Getagraph.com logo
S&P 500
(0.32%) 5 116.11 points
Dow Jones
(0.30%) 38 356 points
Nasdaq
(0.37%) 15 987 points
Oil
(-0.95%) $83.05
Gas
(5.36%) $2.03
Gold
(0.33%) $2 354.90
Silver
(0.54%) $27.68
Platinum
(4.24%) $961.20
USD/EUR
(-0.27%) $0.932
USD/NOK
(-0.45%) $10.98
USD/GBP
(-0.59%) $0.796
USD/RUB
(1.63%) $93.37

リアルタイムの更新： Immuneering Corporation [IMRX]

取引所: NASDAQ セクター: Healthcare 産業: Biotechnology
Upcoming Earnings Alert

3 days till quarter result
(bmo 2024-05-02)

Expected move: +/- 15.06%

最終更新日時30 4月 2024 @ 01:50
25% discount on Stockinvest.us - Use code: Podcast

2.78% $ 1.511

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:50):
Profile picture for Immuneering Corporation

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors...

Stats
本日の出来高 161 982
平均出来高 718 693
時価総額 44.80M
EPS $0 ( 2024-03-04 )
次の収益日 ( $-0.450 ) 2024-05-02
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.800
ATR14 $0.00500 (0.33%)
Insider Trading
Date Person Action Amount type
2024-04-01 Cormorant Asset Management, Lp Sell 100 Class A Common Stock
2024-04-01 Cormorant Asset Management, Lp Sell 300 Class A Common Stock
2024-04-01 Cormorant Asset Management, Lp Sell 100 Class A Common Stock
2024-04-01 Cormorant Asset Management, Lp Sell 600 Class A Common Stock
2024-04-01 Cormorant Asset Management, Lp Sell 10 Class A Common Stock
INSIDER POWER
6.59
Last 92 transactions
Buy: 3 241 516 | Sell: 1 367 921

ボリューム 相関

長: 0.03 (neutral)
短: 0.35 (neutral)
Signal:(64.778) Neutral

Immuneering Corporation 相関

10 最も正の相関
PAIC0.952
SVAC0.945
TIL0.941
BLPH0.933
FTOC0.932
TFFP0.929
LNSR0.928
SVOK0.927
FTOCU0.927
NRBO0.921
10 最も負の相関
NETE-0.972
MMAC-0.953
SASR-0.949
STIM-0.943
BSRR-0.942
HMST-0.94
ISTR-0.939
FNCB-0.939
IART-0.939
BOCH-0.934

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Immuneering Corporation 相関 - 通貨/商品

The country flag -0.09
( neutral )
The country flag 0.15
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.39
( neutral )

Immuneering Corporation 財務諸表

Annual 2023
収益: $0
総利益: $-764 138 (0.00 %)
EPS: $-1.880
FY 2023
収益: $0
総利益: $-764 138 (0.00 %)
EPS: $-1.880
FY 2022
収益: $316 952
総利益: $158 830 (50.11 %)
EPS: $-1.870
FY 2021
収益: $2.08M
総利益: $927 000 (44.57 %)
EPS: $-2.46

Financial Reports:

No articles found.

Immuneering Corporation

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。